Choosing the Right Target at the Right Time

Choosing among several possible targets is becoming one of the most practical challenges in modern gynecologic oncology. The faculty explain that although cross trial comparison has clear limitations, clinicians still need to synthesize efficacy signals, biomarker results, toxicity profiles, and patient priorities when deciding which therapy to use first. A tumor may appear to qualify for more than one targeted treatment, yet the most active option on paper may not be the best starting point if the patient has neuropathy, ocular risk, limited marrow reserve, gastrointestinal vulnerability, or competing quality of life concerns. The discussion makes clear that treatment selection is not a purely laboratory driven exercise. Expression level matters, but so do disease tempo, prior therapy, performance status, and the need to preserve future options. As more antibody drug conjugates enter practice, individualized clinical judgment becomes even more important. Effective decision making will depend on integrating biology with real world considerations that shape whether patients can tolerate and benefit from therapy over time.